Navigation Links
Kensey Nash Corporation Adopts Cash Dividend Policy; Declares Initial Quarterly Dividend of $0.25 per Share
Date:1/3/2012

EXTON, Pa., Jan. 3, 2012 /PRNewswire/ -- The board of directors of Kensey Nash Corporation (Nasdaq: KNSY) announced today that the board has declared a cash dividend of $0.25 per share of the Company's common stock, payable to stockholders of record on January 31, 2012.  The dividend will be paid on February 29, 2012.  This declaration reflects the initial dividend under a new policy whereby the board of directors expects to declare a total annual dividend of $1.00 per share of common stock, to be paid in equal quarterly installments, commencing with the dividend announced today.  Any decision to pay future cash dividends will, however, be made by the board of directors and will depend on the Company's future earnings and financial condition and other relevant factors.

On an annualized basis, the quarterly dividend announced today represents a yield of 5.2% based upon the $19.19 per share closing price of the Company's common stock on the NASDAQ Global Select Market on December 30, 2011.

"The decision to initiate a quarterly cash dividend to our stockholders at this time reflects the confidence of our board of directors in our business model, financial strength and future prospects," commented Joe Kaufmann, President and CEO of the Company.  He added, "We are committed to our research and development programs and continued pursuit of complementary acquisitions and believe that we can meet our goals as a growth-oriented company and also return cash to our stockholders." Mr. Kaufmann further remarked, "Although we are optimistic about the ultimate outcome of our dispute with St. Jude Medical, we believe we can accomplish our objectives and implement this dividend policy regardless of the resolution of those matters." Mr. Kaufmann concluded, "We expect that this new dividend policy will, in the near term, replace stock repurchases as part of our ongoing efforts to maximize stockholder value and related return on investment for our stockholders.  Since 2008, we have repurchased approximately $115 million of our common stock."

About Kensey Nash Corporation. Kensey Nash Corporation is a medical device company primarily focused on regenerative medicine utilizing its proprietary collagen and synthetic polymer technology. The Company is recognized as a leader for innovative product development and unique technology in the field of resorbable biomaterials. The Company has an extensive range of products, which are sold through strategic partners in multiple medical markets, including the cardiology, orthopaedic, sports medicine, spine, endovascular and general surgery markets. For more information, visit www.kenseynash.com.

Cautionary Note for Forward-Looking Statements. This press release contains forward-looking statements that reflect the Company's current expectations about its prospects and opportunities and are covered by the "Safe Harbor for Forward-Looking Statements" provided by the Private Securities Litigation Reform Act of 1995. The Company has tried to identify the forward-looking-statements by using words such as "plan," "expect," "will," "would," "should," "believe," "guidance" and similar expressions, but these words are not the exclusive means for identifying such statements. The Company's expectation that dividends will be paid on a quarterly basis assumes that the Company's financial condition will permit payment under Delaware law, that the Company will generate sufficient cash flow to warrant the payment of a dividend, and that the declaration and payment of cash dividends can be made in accordance with applicable law and agreements of the Company.  The Company also cautions that a number of other risks, uncertainties and other important factors could cause the Company's actual results to differ materially from those expressed in, or implied by, the forward-looking statements, and therefore impact the board of directors' determination of future dividend payments, including, without limitation, the Company's mediation with St. Jude Medical and any other legal proceeding relating to the Company's disputes with St. Jude Medical (including the uncertainty of any outcome thereof and the incurrence of expenses, the diversion of management's time and attention and any disruption to normal business operations and to the Company's relationship with St. Jude Medical, in each case in connection therewith), the Company's success in and the uncertainty of transitioning the Norian manufacturing operations to the Company and Synthes success in distributing the Norian products, St. Jude Medical's success in selling the Angio-Seal device and the extent to which St. Jude Medical is able to and does in fact rely on its internal manufacturing to fulfill its requirements for collagen plugs for the Angio-Seal device, the success of the Company's customers and partners (including St. Jude Medical, Arthrex, Stryker and Synthes) in selling Kensey Nash related products in the marketplace, the Company's success in its research and development efforts (including in its cartilage repair, extracellular matrix and adhesive materials programs), the success of clinical trials in both the U.S. and outside the U.S. to support regulatory approval of the Company's products, and competition from other technologies, as well as tax and other risks associated with healthcare reform, general economic conditions and foreign currency fluctuations. For a detailed discussion of factors that could affect the Company's future operating results, please see the Company's SEC filings, including the disclosures under "Risk Factors" in those filings. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.

 


'/>"/>
SOURCE Kensey Nash Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Kensey Nash to Enter Into Mediation with St. Jude Medical over Angio-Seal Contract Disputes
2. Kensey Nash Corporation Receives $1.9m NIH Grant for Tendon Product Research
3. Kensey Nash Corporation Announces Its First Quarter Fiscal Year 2012 Earnings Release Date and Teleconference
4. Kensey Nash Investor to Present at the Jefferies Global Healthcare Conference in London
5. Kensey Nash Investor Conference Schedule
6. Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2011 Financial Results
7. Kensey Nash Corporation Announces Its Fourth Quarter and Fiscal Year End 2011 Earnings Release Date and Teleconference
8. Kensey Nash Announces New Unsecured Revolving Credit Facility
9. Kensey Nash to Present at the Jefferies 2011 Global Healthcare Conference
10. Kensey Nash Corporation Announces Its Third Quarter Fiscal Year 2011 Earnings Release Date and Teleconference
11. Kensey Nash to Present at the Canaccord Genuity Musculoskeletal Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... 2016 According to market research ... Growth and Demand Forecast to 2022 - Industry Insights ... Field, Very High Field, Low to Mid Field, and ... Spine, Musculoskeletal, Vascular, Breast, Pelvic and Abdomen, Cardiac, and ... (MRI) market was valued at $5,351.7 million in 2015, ...
(Date:5/3/2016)... Norgine B.V. und ... entscheidenden Meilenstein durch diese Veröffentlichung zur  Hepatischen ... um Patientenresultate  bei Verdauungs- und Lebererkrankungen zu ... Verständnis der Hepatischen Enzephalopathie bei und hebt ... Enzephalopathie in der Öffentlichkeit zu schaffen und ...
(Date:5/2/2016)... 2016  Celsion Corporation (NASDAQ: CLSN ), ... from the first cohort of patients in its ... Study) combining GEN-1, the Company,s DNA-based immunotherapy, with ... newly-diagnosed patients with advanced ovarian cancer who will ... In the first three patients dosed, GEN-1 plus ...
Breaking Medicine Technology:
(Date:5/4/2016)... New York, NY (PRWEB) , ... May 04, ... ... country’s leading private owners, developers and operators of commercial real estate proudly announced ... its 2015 Heart Health initiative. Team members portfolio-wide will continue Olshan Properties’ ...
(Date:5/4/2016)... MD (PRWEB) , ... May 04, 2016 , ... ... Ostomy and Continence Nurses (WOCN) Society™ and Canadian Association for Enterostomal Therapy ... event promotion, time saving and planning tools to attendees and exhibitors for the ...
(Date:5/4/2016)... Gilmer, TX (PRWEB) , ... May 04, 2016 ... ... commencement of a master charity program created to assist the people of their ... working closely with nonprofit organizations and community leaders. Their hope is to bring ...
(Date:5/4/2016)... , ... May 04, 2016 , ... ... 2016. SS&A teamed up with one of the top website design companies to ... contains informative legal articles related to the law firm's main practice areas. These ...
(Date:5/4/2016)... ... 2016 , ... Nordic Naturals announces another breakthrough innovation—Omega Curcumin, ... synergistic combination of omega-3 fatty acids and potent antioxidants contains 1000 mg concentrated ... and 200 mg of N-Acetylcysteine (NAC). , Each nutrient plays a distinct ...
Breaking Medicine News(10 mins):